Megan Melody, MD

Dr. Shah describes the clinical and functional assessments he uses when evaluating patients with large B-cell lymphoma for CAR T-cell therapy.

Dr. Melody and Dr. Perales discuss how comorbidities should be considered when evaluating patients with large B-cell lymphoma for CAR T-cell therapy.

Dr. Melody introduces a clinical scenario involving Mr. R, a 71-year-old patient with relapsed large B-cell lymphoma, well-controlled hypertension, mild stable chronic kidney disease, preserved independence, and strong caregiver support.

Dr. Perales discusses how clinicians should interpret real-world evidence alongside pivotal clinical trial data in large B-cell lymphoma.

Dr. Shah discusses why real-world evidence (RWE) is particularly important in large B-cell lymphoma, where the three approved CAR T-cell products were evaluated in separate pivotal trials rather than direct head-to-head comparisons.

Dr. Megan Melody introduces the program and welcomes Dr. Miguel Perales and Dr. Nirav Shah before framing the discussion around the evolving role of real-world evidence in large B-cell lymphoma (LBCL).

Experts weigh ctDNA blood tests in lymphoma, highlighting phased-variant assays for end-of-therapy sensitivity and future tech advances.

How ctDNA trends after CAR T reshape relapse monitoring, pairing MRD blood tests with PET scans to gauge response and relapse risk.

Can ctDNA and interim PET guide shorter DLBCL chemo? Experts weigh de-escalation to cut toxicity, urging randomized trials.

Can ctDNA and interim PET guide shorter DLBCL chemo? Experts weigh de-escalation to reduce toxicity and urge randomized trials.

Alpha-3 sparks debate on treating ctDNA-positive lymphoma early—can allo CAR T or bispecifics erase MRD without excess toxicity?

Can ctDNA spot relapse early and justify treating "molecular" lymphoma? Alpha-3 tests allo CAR T, weighing toxicity, MRD clearance, survival.

Megan Melody, MD, discusses the importance of female mentorship on her career development as a hematologist/oncologist.